🩺 Imfinzi scores third pivotal win in bladder cancer
🩺 Imfinzi scores third pivotal win in bladder cancer
AstraZeneca’s Phase III VOLGA trial in 695 cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer found that perioperative Imfinzi plus Padcev significantly improved both event-free survival and overall survival versus standard care. The study adds a third late-stage bladder cancer win for durvalumab, while the Imfinzi/Imjudo/Padcev arm improved event-free survival but has not yet shown a statistically significant overall survival benefit.
Why It Matters To Oncology
VOLGA targets a high-need muscle-invasive bladder cancer population: patients undergoing radical cystectomy who cannot receive or have declined cisplatin.
AstraZeneca says up to 50% of patients with MIBC are ineligible for cisplatin-based chemotherapy, often because of renal impairment or comorbidities.
If confirmed in full data, the regimen could help refine perioperative treatment decisions in Bladder Cancer beyond cisplatin-eligible patients.
Safety was consistent with known profiles for Imfinzi, Imjudo and Padcev, with no new signals identified.
The Financials
VOLGA is AstraZeneca’s third positive pivotal readout in bladder cancer, alongside NIAGARA and POTOMAC, strengthening Imfinzi’s franchise in early-stage, curative-intent disease.
Imfinzi is already approved in more than 40 countries for cisplatin-eligible MIBC based on NIAGARA, and is under review in several markets for high-risk non-MIBC after POTOMAC.
Positive survival data in a cisplatin-ineligible setting could expand the addressable perioperative market for durvalumab and support additional regulatory filings.
What They're Saying
VOLGA coordinating investigator Thomas Powles said these patients face high recurrence rates even after bladder removal, underscoring the need for effective, well-tolerated options.
AstraZeneca oncology R&D chief Susan Galbraith called VOLGA the company’s third positive bladder cancer readout and said it helps position Imfinzi as an immunotherapy backbone in early-stage disease.
The company said data will be presented at a future medical meeting and shared with global regulators.
What's Next
A later analysis will reassess overall survival in the Imfinzi plus Imjudo plus Padcev arm, where only a favorable trend has been seen so far.
Clinicians will be watching for full hazard ratios, subgroup analyses and perioperative treatment details when VOLGA is presented.
Regulatory submissions could follow if the detailed data support a favorable benefit-risk profile in cisplatin-ineligible MIBC.